Current developments in anti-HIV/AIDS gene therapy
- PMID: 19197791
Current developments in anti-HIV/AIDS gene therapy
Abstract
Since the introduction of highly active retroviral therapy (HAART) in 1996, dramatic improvements in therapeutic treatment modalities for HIV type 1 (HIV-1) infection have occurred. Potent drug combinations in HAART regimens efficiently block HIV-1 replication in most patients; however, multiple shortcomings of HAART are apparent and require novel treatments that can be utilized in combination with HAART or as stand-alone therapies. Gene therapy of HIV-1 represents one such treatment and several strategies are currently under development. This review focuses on advancements in the gene therapy of HIV/AIDS by highlighting the progress made in selecting new therapeutic targets and developing novel tools to exert an effect on these targets. In addition, new trends emerging from this progress are summarized. This review is based primarily on literature published between 2006 and 2008.
Similar articles
-
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review.
-
Progress and prospects: RNA-based therapies for treatment of HIV infection.Gene Ther. 2007 Jul;14(14):1057-64. doi: 10.1038/sj.gt.3302977. Gene Ther. 2007. PMID: 17607313 Review.
-
Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen.J Gene Med. 2003 Aug;5(8):645-53. doi: 10.1002/jgm.436. J Gene Med. 2003. PMID: 12898634 Review.
-
Gene therapy progress and prospects: novel gene therapy approaches for AIDS.Gene Ther. 2005 Mar;12(6):467-76. doi: 10.1038/sj.gt.3302488. Gene Ther. 2005. PMID: 15703764 Review.
-
Retroviral vectors for gene therapy of AIDS and cancer.Curr Opin Mol Ther. 2001 Oct;3(5):468-75. Curr Opin Mol Ther. 2001. PMID: 11699891 Review.
Cited by
-
Targeting frameshifting in the human immunodeficiency virus.Expert Opin Ther Targets. 2012 Mar;16(3):249-58. doi: 10.1517/14728222.2012.665879. Expert Opin Ther Targets. 2012. PMID: 22404160 Free PMC article. Review.
-
siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection.Viral Immunol. 2014 Jun;27(5):207-13. doi: 10.1089/vim.2013.0126. Epub 2014 May 16. Viral Immunol. 2014. PMID: 24834927 Free PMC article.
-
Digoxin suppresses HIV-1 replication by altering viral RNA processing.PLoS Pathog. 2013 Mar;9(3):e1003241. doi: 10.1371/journal.ppat.1003241. Epub 2013 Mar 28. PLoS Pathog. 2013. PMID: 23555254 Free PMC article.
-
Current progress in the development of RNAi-based therapeutics for HIV-1.Gene Ther. 2011 Dec;18(12):1134-8. doi: 10.1038/gt.2011.149. Epub 2011 Sep 29. Gene Ther. 2011. PMID: 21956690 Free PMC article. Review.
-
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.Mol Ther. 2013 Jan;21(1):192-200. doi: 10.1038/mt.2012.226. Epub 2012 Nov 20. Mol Ther. 2013. PMID: 23164935 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical